Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference

    Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global
                            Healthcare Conference

PR Newswire

CHESTERBROOK, Pa., Feb. 12, 2013

CHESTERBROOK, Pa., Feb. 12, 2013 /PRNewswire/ --Auxilium Pharmaceuticals,
Inc. (Nasdaq: AUXL) today announced that executive management will participate
in the Leerink Swann Global Healthcare Conference to be held February 13-14,
2013 at the Waldorf Astoria Hotel in New York City. Mr. Adrian Adams, Chief
Executive Officer and President, is scheduled to present an overview of the
Company and its product pipeline at 2:30 p.m. ET on Thursday, February 14,

(Logo: )

The presentation will also be webcast on the "For Investors" section of the
Auxilium website under the "Events" tab on February 14, 2013. To access the
live webcast, please log on to Auxilium's website approximately fifteen
minutes prior to the presentation to register and download any necessary audio
software. The presentation replay will be available for ninety days after the

About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a
focus on developing and marketing products to predominantly specialist
audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical
treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum)
for the treatment of adult Dupuytren's contracture patients with a palpable
cord in the U.S. GSK co-promotes Testim with Auxilium in the U.S. Ferring
International Center S.A. markets Testim in certain countries of the EU and
Paladin Labs Inc. markets Testim in Canada. Pfizer has marketing rights for
XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46
countries in Eurasia through April 24, 2013; Asahi Kasei Pharma Corporation
has development and commercial rights for XIAFLEX in Japan; and Actelion
Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in
Canada, Australia, Brazil and Mexico. The sBLA for XIAFLEX for the treatment
of Peyronie's disease was submitted to the FDA in November 2012.
Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of
development for the treatment of Frozen Shoulder syndrome (adhesive
capsulitis) and phase Ib of development for the treatment of cellulite
(edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue
additional indications for CCH. For additional information, visit


This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995, including statements made
with respect to Auxilium's strategy, progress and timing of development
programs and related trials, the efficacy of its product candidates, the
commercial benefits available to it as a result of its agreements with third
parties, future operations, financial position, future revenues, projected
costs, prospects, plans and objectives of management and other statements
regarding matters that are not historical facts, and involve predictions.
These statements involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance, achievements or prospects
to be materially different from any future results, performance, achievements
or prospects expressed in or implied by such forward-looking statements. In
some cases you can identify forward-looking statements by terminology such as
''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'',
''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of
these terms or similar expressions, although not all forward-looking
statements contain these identifying words. Although forward-looking
statements are based on Auxilium's current plans or assessments that are
believed to be reasonable as of the date of this press release, they
inherently involve certain risks and uncertainties. These forward-looking
statements are subject to a number of risks and uncertainties, including those
discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for
the year ended December 31, 2011, each of Auxilium's Quarterly Reports on Form
10-Q for the three months ended September 30, 2012, June 30, 2012 and March
31, 2012 and Auxilium's preliminary prospectus supplement and Current Report
on Form 8-K, each filed with the Securities and Exchange Commission (the
"SEC") on January 23, 2013. While Auxilium may elect to update the
forward-looking statements made in this news release in the future, Auxilium
specifically disclaims any obligation to do so. Auxilium's SEC filings may be
accessed electronically by means of the SEC's home page on the Internet at There may be additional risks that Auxilium does not
presently know or that Auxilium currently believes are immaterial which could
also cause actual results to differ from those contained in the
forward-looking statements.

For More Information, Contact:

James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900

William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900

SOURCE Auxilium Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.